FDA Approval Sought for Brentuximab Vedotin in Frontline CD30+ PTCL

November 5, 2018 – A supplemental biologics license application (sBLA) has been submitted to the FDA for the use of brentuximab vedotin in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL). The sBLA is based on the phase III ECHELON-2 trial, in which combining frontline brentuximab vedotin with CHP (cyclophosphamide, doxorubicin, prednisone) reduced the risk of death … (leggi tutto)